Overview
Immunai is a biotechnology company founded in December 2018[4] headquartered at 430 E 29th St, New York, NY 10016, USA[2], with additional offices in Tel Aviv, Prague and Zurich[12]. The company maps the immune system at single-cell scale using machine learning to facilitate development of immune-related therapeutics[1]. Central to its platform is AMICA, described as the world's largest immune-focused harmonized single-cell database[6]. Immunai offers three solutions along the drug development journey: Target Discovery, Preclinical Evaluation and Clinical Trial Optimization[5]. The company built AMICA through acquisitions of Dropprint Genomics in March 2021 and Nebion in July 2021[9]. Immunai partners with biopharmaceutical companies including AstraZeneca on oncology and inflammatory bowel disease programs[7][8] and Teva on vitiligo research[7]. The company's team includes over 80 PhDs[11] and counts KDT and Alexandria Venture Investments among its leading investors[10].
Headquarters at 430 E 29th St, New York, NY 10016, USA [2]
Immunai states it was "Founded in December 2018" with a mission to revolutionize drug discovery and development. [4]
Immunai sells three solutions along the drug development journey: Target Discovery, Preclinical Evaluation and Clinical Trial Optimization, delivered through a Generate-Augment-Compute-Validate-Recommend workflow. [5]
Central to Immunai's platform is AMICA, which the company calls "the world's largest immune-focused, harmonized single-cell database." [6]
Immunai says it is headquartered in NYC with offices in Tel Aviv, Prague and Zurich. [12]
Business address: 180 Varick Street, New York, New York, 10014. [14]
Partnerships
Immunai highlights collaborations with AstraZeneca on IBD target discovery and with Teva on vitiligo disease mechanism and biomarker discovery for Teva's IL15 targeted antibody. [7]
On May 11, 2026 Immunai announced that "AstraZeneca expands AI oncology collaboration with Immunai." [8]
Funding history
Immunai names KDT and Alexandria Venture Investments among its leading investors. [10]
Growth & traction
Immunai says its team includes 80+ PhDs. [11]
Recent developments
- Immunai's careers page listed 12 open roles across Deep Analytics (4), External Collaborations (3), Software Engineering (3), Product (1) and Lab Operations (1), split between Ramat Gan, IL (8) and New York, US (4).[13]
Status
- Immunai built AMICA through two acquisitions: it acquired Dropprint Genomics, a Y-Combinator-backed single-cell genomics software company, in March 2021, and Nebion, a biocuration and data integration company, in July 2021.[9]
Something wrong or missing? Send an update. Fixed within 24 hours.